Replicor宣布发表REP 401研究报告，该研究在慢性乙型肝炎患者

StephenW

回复 乙肝人1949 的帖子

"这个和长效+核苷3o%的总治愈率一样"  - 我相信这是错的, 更像是10％.

Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis.
Ahn SH1, Marcellin P2, Ma X3, Caruntu FA4, Tak WY5, Elkhashab M6, Chuang WL7, Tabak F8, Mehta R9, Petersen J10, Guyer W1, Jump B11, Chan A11, Subramanian M11, Crans G11, Fung S12, Buti M13, Gaeta GB14, Hui AJ15,16, Papatheodoridis G17, Flisiak R18, Chan HLY19.
Author information
Erratum in

    Correction to: Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis. [Dig Dis Sci. 2019]

Abstract
BACKGROUND AND AIMS:

Hepatitis B surface antigen (HBsAg) loss is the ideal clinical endpoint but is achieved rarely during oral antiviral treatment. A current unmet need in CHB management is achievement of HBsAg loss with a finite course of oral antiviral therapy, thereby allowing discontinuation of treatment. Significantly higher rates of HBsAg loss at 72 weeks post-treatment have been demonstrated when tenofovir disoproxil fumarate (TDF) was combined with pegylated interferon (PEG-IFN) for 48 weeks compared with either monotherapy. This analysis provides follow-up data at week 120.
METHODS:

In an open-label, active-controlled study, 740 patients with chronic hepatitis B were randomly assigned to receive TDF plus PEG-IFN for 48 weeks (group A), TDF plus PEG-IFN for 16 weeks followed by TDF for 32 weeks (group B), TDF for 120 weeks (group C), or PEG-IFN for 48 weeks (group D). Efficacy and safety at week 120 were assessed.
RESULTS:

Rates of HBsAg loss at week 120 were significantly higher in group A (10.4%) than in group B (3.5%), group C (0%), and group D (3.5%). Rates of HBsAg loss and HBsAg seroconversion in group A were significantly higher than rates in group C (P < 0.001 for both) or group D (HBsAg loss: P = 0.002; HBsAg seroconversion: P < 0.001).
CONCLUSIONS:

The results of this analysis confirm the results from earlier time points which demonstrate the increased rate of HBsAg loss in patients treated with a finite course of PEG-IFN plus TDF compared with the rates in patients receiving either monotherapy.
KEYWORDS:

Chronic hepatitis B; HBsAg loss; HBsAg seroconversion; Virological response

替诺福韦富马酸替诺福韦酯加聚乙二醇干扰素Alfa-2a引起的乙型肝炎表面抗原损失：第120周分析。
Ahn SH1，Marcellin P2，Ma X3，Caruntu FA4，Tak WY5，Elkhashab M6，Chuang WL7，Tabak F8，Mehta R9，Petersen J10，Guyer W1，Jump B11，Chan A11，Subramanian M11，Crans G11，Fung S12，Buti M13 ，Gaeta GB14，Hui AJ15,16，Papatheodoridis G17，Flisiak R18，Chan HLY19。
作者信息
勘误

    校正至：替诺福韦酯富马酸吡索非尔加聚乙二醇干扰素Alfa-2a引起的乙型肝炎表面抗原损失：第120周分析。 [Dig Dis Sci。 2019]

抽象
背景与目的：

乙型肝炎表面抗原（HBsAg）丢失是理想的临床终点，但在口服抗病毒治疗期间很少达到。 CHB管理中当前未满足的需求是通过有限的口服抗病毒治疗疗程实现HBsAg的流失，从而可以中止治疗。与任何一种单一疗法相比，当替诺福韦富马酸替诺福韦（TDF）与聚乙二醇干扰素（PEG-IFN）联合治疗48周时，治疗后72周的HBsAg丢失率显着提高。该分析提供了第120周的随访数据。
方法：

在一项开放标签，主动对照研究中，将740名慢性乙型肝炎患者随机分配接受TDF + PEG-IFN治疗48周（A组），TDF + PEG-IFN治疗16周，然后接受TDF 32周（ B组），TDF 120周（C组）或PEG-IFN 48周（D组）。在第120周时评估疗效和安全性。
结果：

A组（10.4％）在第120周的HBsAg丢失率显着高于B组（3.5％），C组（0％）和D组（3.5％）。 A组的HBsAg丧失和HBsAg血清转化率显着高于C组（两者均P << 0.001）或D组（HBsAg丧失：P = 0.002； HBsAg血清转化：P <0.001）。
结论：

该分析的结果证实了较早时间点的结果，这些结果表明，接受有限疗程的PEG-IFN加TDF治疗的患者与接受任一单一疗法的患者相比，HBsAg丢失率增加。
关键字：

慢性乙型肝炎； HBsAg丢失； HBsAg血清转化；病毒学反应

齐欢畅

关注

newchinabok

StephenW 发表于 2020-3-10 21:59
回复 乙肝人1949 的帖子

"这个和长效+核苷3o%的总治愈率一样"  - 我相信这是错的, 更像是10％.

本本主义，毛主席一辈子最痛恨的就是本本主义，马克思的理论上了天，有什么用？rep十几年，乙克十几年，乐复能十几年有什么用？能治病么？一切从本本出发，不从实际出发，有毛用？真的假的都分不清，还谈这些有毛用

傻狍子7号

这个药虽然报道的效果还行，但真实性让人怀疑。

傻狍子7号

之前这家公司在官网pipeline写了欧洲、美洲具体的推进时间，就在2020年。结果后面全变成in planning stage了。对其实验真实性表示怀疑。